ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.26 Million USD | 16.82% |
| 2022 | -8.73 Million USD | 3.54% |
| 2021 | -9.05 Million USD | -5.81% |
| 2020 | -8.55 Million USD | -2.43% |
| 2019 | -8.35 Million USD | -36.24% |
| 2018 | -6.13 Million USD | 3.15% |
| 2017 | -6.33 Million USD | -81.36% |
| 2016 | -3.49 Million USD | -14.21% |
| 2015 | -3.05 Million USD | 40.69% |
| 2014 | -5.15 Million USD | -65.69% |
| 2013 | -3.11 Million USD | -49.49% |
| 2012 | -2.08 Million USD | -7.34% |
| 2011 | -1.93 Million USD | 52.27% |
| 2010 | -4.06 Million USD | -53.06% |
| 2009 | -2.65 Million USD | -119.26% |
| 2008 | -1.21 Million USD | 45.85% |
| 2007 | -2.23 Million USD | 41.79% |
| 2006 | -3.83 Million USD | -20.74% |
| 2005 | -3.17 Million USD | 17.58% |
| 2004 | -3.85 Million USD | -613.31% |
| 2003 | -540.81 Thousand USD | -15667.26% |
| 2002 | -3430.00 USD | -66.91% |
| 2001 | -2055.00 USD | 43.09% |
| 2000 | -3611.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.22 Million USD | -545.03% |
| 2024 Q1 | -1.27 Million USD | 32.73% |
| 2023 Q1 | -1.97 Million USD | 25.31% |
| 2023 FY | -7.26 Million USD | 16.82% |
| 2023 Q4 | -1.89 Million USD | -20.62% |
| 2023 Q3 | -1.57 Million USD | 13.79% |
| 2023 Q2 | -1.82 Million USD | 7.43% |
| 2022 Q4 | -2.63 Million USD | -31.88% |
| 2022 FY | -8.73 Million USD | 3.54% |
| 2022 Q2 | -2.06 Million USD | -2.03% |
| 2022 Q3 | -2 Million USD | 3.26% |
| 2022 Q1 | -2.02 Million USD | 35.94% |
| 2021 Q3 | -2.05 Million USD | -17.52% |
| 2021 Q1 | -2.08 Million USD | -18.72% |
| 2021 Q4 | -3.16 Million USD | -53.88% |
| 2021 Q2 | -1.74 Million USD | 16.04% |
| 2021 FY | -9.05 Million USD | -5.81% |
| 2020 Q3 | -3.36 Million USD | -226.68% |
| 2020 Q2 | -1.02 Million USD | 57.2% |
| 2020 FY | -8.55 Million USD | -2.43% |
| 2020 Q1 | -2.4 Million USD | 36.23% |
| 2020 Q4 | -1.75 Million USD | 47.84% |
| 2019 Q4 | -3.77 Million USD | -139.72% |
| 2019 Q1 | -967.85 Thousand USD | 40.16% |
| 2019 Q2 | -2.03 Million USD | -110.49% |
| 2019 FY | -8.35 Million USD | -36.24% |
| 2019 Q3 | -1.57 Million USD | 22.74% |
| 2018 Q1 | -1.68 Million USD | 35.18% |
| 2018 Q3 | -1.49 Million USD | -11.96% |
| 2018 FY | -6.13 Million USD | 3.15% |
| 2018 Q4 | -1.61 Million USD | -8.19% |
| 2018 Q2 | -1.33 Million USD | 20.68% |
| 2017 FY | -6.33 Million USD | -81.36% |
| 2017 Q2 | -881.44 Thousand USD | -11.4% |
| 2017 Q1 | -791.27 Thousand USD | -23.12% |
| 2017 Q4 | -2.59 Million USD | -26.02% |
| 2017 Q3 | -2.06 Million USD | -133.78% |
| 2016 FY | -3.49 Million USD | -14.21% |
| 2016 Q4 | -642.65 Thousand USD | 5.09% |
| 2016 Q3 | -677.11 Thousand USD | 55.75% |
| 2016 Q2 | -1.53 Million USD | -138.87% |
| 2016 Q1 | -640.55 Thousand USD | 3.49% |
| 2015 Q2 | -1.04 Million USD | -85.23% |
| 2015 FY | -3.05 Million USD | 40.69% |
| 2015 Q4 | -663.74 Thousand USD | 15.8% |
| 2015 Q3 | -788.3 Thousand USD | 24.33% |
| 2015 Q1 | -562.44 Thousand USD | 77.3% |
| 2014 Q2 | -800.71 Thousand USD | -2.82% |
| 2014 Q1 | -778.75 Thousand USD | 3.18% |
| 2014 FY | -5.15 Million USD | -65.69% |
| 2014 Q4 | -2.47 Million USD | -125.93% |
| 2014 Q3 | -1.09 Million USD | -36.93% |
| 2013 Q4 | -804.31 Thousand USD | 9.44% |
| 2013 Q3 | -888.15 Thousand USD | -0.65% |
| 2013 Q2 | -882.4 Thousand USD | -64.83% |
| 2013 FY | -3.11 Million USD | -49.49% |
| 2013 Q1 | -535.33 Thousand USD | -22.13% |
| 2012 Q4 | -438.32 Thousand USD | 32.9% |
| 2012 Q2 | -481.78 Thousand USD | 5.01% |
| 2012 Q3 | -653.26 Thousand USD | -35.59% |
| 2012 FY | -2.08 Million USD | -7.34% |
| 2012 Q1 | -507.21 Thousand USD | 47.27% |
| 2011 Q4 | -961.88 Thousand USD | -237.77% |
| 2011 Q1 | -427.88 Thousand USD | 41.21% |
| 2011 Q2 | -263.75 Thousand USD | 38.36% |
| 2011 Q3 | -284.77 Thousand USD | -7.97% |
| 2011 FY | -1.93 Million USD | 52.27% |
| 2010 Q1 | -962.93 Thousand USD | -27.76% |
| 2010 Q2 | -1.81 Million USD | -88.75% |
| 2010 Q3 | -552.81 Thousand USD | 69.58% |
| 2010 Q4 | -727.79 Thousand USD | -31.65% |
| 2010 FY | -4.06 Million USD | -53.06% |
| 2009 Q2 | -313.94 Thousand USD | 40.65% |
| 2009 Q4 | -753.69 Thousand USD | 28.66% |
| 2009 Q3 | -1.05 Million USD | -236.54% |
| 2009 FY | -2.65 Million USD | -119.26% |
| 2009 Q1 | -528.96 Thousand USD | -138.67% |
| 2008 Q3 | -252.33 Thousand USD | 44.86% |
| 2008 Q1 | -278.47 Thousand USD | 36.22% |
| 2008 FY | -1.21 Million USD | 45.85% |
| 2008 Q2 | -457.61 Thousand USD | -64.33% |
| 2008 Q4 | -221.62 Thousand USD | 12.17% |
| 2007 Q4 | -436.6 Thousand USD | 36.92% |
| 2007 Q1 | -640.98 Thousand USD | 39.22% |
| 2007 Q2 | -464.98 Thousand USD | 27.46% |
| 2007 Q3 | -692.11 Thousand USD | -48.85% |
| 2007 FY | -2.23 Million USD | 41.79% |
| 2006 FY | -3.83 Million USD | -20.74% |
| 2006 Q2 | -1.18 Million USD | -25.17% |
| 2006 Q3 | -644.44 Thousand USD | 45.83% |
| 2006 Q4 | -1.05 Million USD | -63.63% |
| 2006 Q1 | -950.41 Thousand USD | 1.26% |
| 2005 Q2 | -291.91 Thousand USD | 15.02% |
| 2005 Q4 | -962.58 Thousand USD | 40.27% |
| 2005 Q1 | -343.5 Thousand USD | 38.13% |
| 2005 FY | -3.17 Million USD | 17.58% |
| 2005 Q3 | -1.61 Million USD | -452.09% |
| 2004 Q2 | -739.1 Thousand USD | 54.18% |
| 2004 FY | -3.85 Million USD | -613.31% |
| 2004 Q4 | -555.17 Thousand USD | 41.58% |
| 2004 Q1 | -1.61 Million USD | -199.95% |
| 2004 Q3 | -950.3 Thousand USD | -28.58% |
| 2003 Q2 | -561.00 USD | 70.4% |
| 2003 FY | -540.81 Thousand USD | -15667.26% |
| 2003 Q4 | -537.8 Thousand USD | -95764.53% |
| 2003 Q1 | -1895.00 USD | -237.79% |
| 2003 Q3 | -561.00 USD | 0.0% |
| 2002 Q2 | -597.00 USD | 63.46% |
| 2002 Q1 | -1634.00 USD | -166.56% |
| 2002 FY | -3430.00 USD | -66.91% |
| 2002 Q4 | -561.00 USD | 12.07% |
| 2002 Q3 | -638.00 USD | -6.87% |
| 2001 Q2 | -620.00 USD | -196.65% |
| 2001 Q4 | -613.00 USD | 0.0% |
| 2001 FY | -2055.00 USD | 43.09% |
| 2001 Q3 | -613.00 USD | 1.13% |
| 2001 Q1 | -209.00 USD | 90.62% |
| 2000 Q4 | -2228.00 USD | -257.62% |
| 2000 Q2 | -460.00 USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | -3611.00 USD | 0.0% |
| 2000 Q3 | -623.00 USD | -35.43% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | -15.23 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -1374.292% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 23.692% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 75.784% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 89.183% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 54.156% |
| Better Therapeutics, Inc. | -38.26 Million USD | 81.018% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 82.738% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 39.323% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 78.54% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 78.898% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 93.304% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -260.572% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 78.639% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 84.531% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -431.16% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 63.574% |
| Molecular Templates, Inc. | -10.46 Million USD | 30.604% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 48.309% |
| NexImmune, Inc. | -29.19 Million USD | 75.12% |
| Orgenesis Inc. | -53.63 Million USD | 86.459% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 85.84% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -9209.525% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 55.015% |
| Scopus BioPharma Inc. | -11.71 Million USD | 38.002% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 98.56% |
| Statera Biopharma, Inc. | -98.34 Million USD | 92.615% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -5.292% |
| Trevena, Inc. | -35.28 Million USD | 79.418% |
| Vaxxinity, Inc. | -58.28 Million USD | 87.539% |
| Vaccinex, Inc. | -22.88 Million USD | 68.263% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -593.712% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 85.673% |